Yiqiao Xin

Education

Ph.D., health economics, University of Glasgow; M.Sc., health technology assessment and management, Université de Montréal; B.Sc., pharmacy, China Pharmaceutical University

Summary of Experience

Dr. Xin specializes in health economics and outcomes research (HEOR). She provides expertise in decision-analytic modeling methods for health technology appraisals (HTA) and has led the design and implementation of cost-effectiveness and budget impact models in multiple countries. Dr. Xin’s work has also involved evidence synthesis such as network meta-analyses and matching-adjusted indirect comparisons, indirect treatment comparisons with individual-level patient data, clinical trial analyses, survey development, and patient-reported outcome (PRO) studies. Her work spans a broad range of disease areas, including oncology, immunology, dermatology, cardiovascular diseases, diabetes, and neurology. Prior to joining Analysis Group, Dr. Xin was a research associate at an academic institution, where she focused on trial- and model-based economic evaluations and PROs, as well as providing expertise on complex literature reviews and developing R Shiny applications for conducting network meta-analysis. Her work has been presented at clinical and economic research conferences and published in various peer-reviewed journals.

Selected Publishing

• Association between event-free survival and overall survival in early-stage triple-negative breast cancer

  Future Oncology, 2023
  2023

  Huang M, Fasching PA, Haiderali A, Xue W, Pan W, Karantza V, Yang F, Truscott J, Xin Y, O'Shaughnessy J

  HEOR, Epidemiology & Market Access

Events

• June 2, 2023

  2023 ASCO Annual Meeting to Feature New Outcomes Research from Analysis Group

  Event: 2023 ASCO Annual Meeting
  
  Host: American Society of Clinical Oncology (ASCO)